Astria Therapeutics Completes Underwritten Offering of Common Stock

Astria Therapeutics Completes Underwritten Offering of Common Stock

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
Astria Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for allergic and immunological diseases, completed its underwritten registered direct offering of 10,340,000 shares of its common stock. The shares were priced on January 30, 2024 at an offering price of $12.09 per share and the offering closed on February 1, 2024. Astria received gross proceeds of approximately $125 million before deducting underwriting discounts and commissions and other offering expenses.  

The WilmerHale team representing Astria consisted of Rosemary Reilly, Molly Fox, Jeffries Oliver-Li, Andrea Sorrentino, Kevin Cheng and Arpi Youssoufian, with assistance from Heidi Treiber, Ben Lobley and Mark Devine. 

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel